Attached files
| file | filename |
|---|---|
| EX-99 - PRESS RELEASE - Viridian Therapeutics, Inc.\DE | newsrelease.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 23, 2015
Signal Genetics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-36483 | 47-1187261 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| Signal Genetics, Inc. 5740 Fleet Street Carlsbad, California |
92008 |
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (760) 537-4100
________________________________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01. Entry into a Material Definitive Agreement.
On September 23, 2015, Signal Genetics, Inc. (the "Company") entered into a Master Service Agreement (the "Agreement"), dated as of September 23, 2015, with a leading biopharmaceutical company.
The first two projects under this Agreement will deploy the Company's proprietary MyPRS® test to inform the clinical stage development program of a novel treatment – including potential combination therapies with current drugs – for patients with multiple myeloma.
This is the second master service agreement the Company has entered into in 2015. The Company and its newest biopharmaceutical partner will commence both projects prior to year-end 2015.
The foregoing is only a brief description of the material terms of the Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder, and is qualified in its entirety by reference to the Agreement.
Item 7.01. Regulation FD Disclosure.
On September 23, 2015, the Company issued a press release entitled "Signal Genetics Announces Master Service Agreement With Major Biopharmaceutical Partner" (the "Press Release"). A copy of the Press Release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
The information contained in Item 7.01 this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for the purposes of Section 18 of the United States Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of Section 18. Furthermore, the information shall not be deemed incorporated by reference into any registration statement or any other filing under the United States Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release, dated September 23, 2015, entitled "Signal Genetics Announces Master Service Agreement With Major Biopharmaceutical Partner."
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Signal Genetics, Inc.
(Registrant) |
||
| September 23, 2015
(Date) |
/s/ TAMARA A. SEYMOUR
Tamara A. Seymour Chief Financial Officer |